FDA WARNING_LETTER - Divyata - September 06, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA and DEA issued a Warning Letter to Divyata on September 6, 2019, for unlawfully selling opioids and other drugs to U.S. consumers via the internet.
**Violations and Deficiencies:**
* **Unlawful Distribution of Controlled Substances:** Divyata is operating as an "online pharmacy" without a modified DEA registration, violating the Ryan Haight Online Pharmacy Consumer Protection Act (RHA), specifically 21 U.S.C. § 841(h) and § 843(c). This includes offering to deliver, distribute, or dispense controlled substances and advertising their sale without proper authorization. * **Unapproved New Drugs:** Divyata introduces unapproved new drugs, such as "Tramadol (Ultram) 100 mg" by "Dimedics," into interstate commerce, violating sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(d), 355(a)]. These drugs lack FDA approval and are not generally recognized as safe and effective for their labeled uses. * **Misbranded Drugs:** The tramadol product is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f
ID · bdbd326c-2f5c-4936-87c8-42844a903b15
Full citation text and observation details available on the Dashboard.